CIBC Asset Management
IBRX icon

CIBC Asset Management’s ImmunityBio IBRX Stock Holding History

CIBC Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,539
Closed -$52.6K – 1210
2024
Q4 		$52.6K Buy
20,539
+1,102
+6% +$4.59K ﹤0.01% 1204
2024
Q3 		$72.3K Buy
19,437
+733
+4% +$3.39K ﹤0.01% 1187
2024
Q2 		$118K Buy
+18,704
New +$123K ﹤0.01% 1088
2023
Q1 		– Sell
-11,161
Closed -$56.6K – 1098
2022
Q4 		$56.6K Sell
11,161
-4,508
-29% -$24.8K ﹤0.01% 1031
2022
Q3 		$78K Hold
15,669
– – ﹤0.01% 1193
2022
Q2 		$58K Sell
15,669
-1,146
-7% -$4.6K ﹤0.01% 1229
2022
Q1 		$94K Hold
16,815
– – ﹤0.01% 1463
2021
Q4 		$102K Buy
16,815
+1,232
+8% +$9.26K ﹤0.01% 1482
2021
Q3 		$152K Buy
+15,583
New +$171K ﹤0.01% 1401

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CIBC Asset Management's IBRX Position: Q1 2025 in Review

CIBC Asset Management sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 20,539 shares — an estimated $52.6K sold.

CIBC Asset Management first reported a position in IBRX in Q3 2021 and held it in 9 quarters. The position peaked at $152K in Q3 2021. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • CIBC Asset Management reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • CIBC Asset Management sold 20,539 ImmunityBio shares in Q1 2025, an estimated $52.6K.
  • CIBC Asset Management first reported a position in ImmunityBio in Q3 2021 and held it in 9 quarters.
  • CIBC Asset Management's ImmunityBio position peaked at $152K in Q3 2021.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on CIBC Asset Management's 13F filing for Q1 2025, filed 13 May 2025.